Abhishek Maiti, MD
Department of Leukemia, Division of Cancer Medicine
About Dr. Abhishek Maiti
Dr. Abhishek Maiti is an Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. He graduated from Nil Ratan Sircar Medical College in India, and completed internal medicine residency at the University of Texas, Houston, followed by a fellowship in hematology/oncology at MD Anderson Cancer Center.
Dr. Maiti's patient care and research focuses on developing novel therapies for leukemias. He has authored several peer-reviewed publications in leading medical journals and presented his research at national and international meetings. His work has received recognition from the American Society of Clinical Oncology, the European Hematology Association, the American Society of Hematology, the Society for Translational Oncology, and others. He has received prestigious national and international awards including the ASCO Young Investigator Award, the Future Leaders in Hematology Award, Leuka International Scholarship, ASCO Endowed Merit Award, the Shannon Timmins Endowed Fellowship, among others.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2010 | Nilratan Sircar Medical College and Hospital, Kolkata, IN, MD |
Postgraduate Training
| 2017-2020 | Clinical Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2014-2017 | Clinical Residency, The University of Texas Health Science Center, Houston, Texas |
| 2010-2011 | Clinical Internship, Nilratan Sircar Medical College and Hospital, Kolkata |
Licenses & Certifications
| 2020 | Hematology, American Board of Medical Specialties |
| 2017 | American Board of Internal Medicine |
| 2017 | Oncology, American Board of Medical Specialties |
Experience & Service
Other Professional Positions
Advisor, Galecto, Copenhagen, 2025 - Present
Consultant, Ingenium Therapeutics, Daejeon, 2025 - Present
Advisory Board Member, Electra Therapeutics, San Francisco, California, 2025 - Present
Co-chair, Steering Committee, SURPASS pivotal trial of ELA-026, Electra Therapeutics, San Francisco, California, 2025 - Present
Advisor, Orum Therapeutics, Daejeon, 2025 - Present
Consultant, Nextech Ventures, Zurich, 2025 - Present
Advisory Board Member, Ferring Ventures (Biotech), Helsinki, 2025 - Present
Steering Committee Member, ImCheck Therapeutics, Marseille, 2023 - Present
Institutional Committee Activities
Member, HLH Workgroup, 2025 - Present
Reviewer, Academic Review Committee, 2025 - Present
Member, Junior Faculty Academic Career Development Committee, 2024 - Present
Workgroup Member, Chronic Myeloid Leukemia - Adult, 2024 - Present
Member, Institutional Review Board #3, 2023 - Present
Member, American Society of Hematology Committee on Practice, 2023 - 2024
Reviewer / Member, Scientific Review Committee # 1, 2022 - Present
Member, Senate Research Affairs Committee, 2021 - Present
Member, Academic and Planning Committee - Division of Education & Training, 2021 - Present
Abstract Reviewer, Academic Review Committee - Division of Education & Training, 2021
Co-Chair, Emil J Freireich Leukemia Hematology Grand Rounds, 2021 - Present
Member, Adult Acute Myeloid Leukemia, 2020 - Present
Member, Institutional Review Board, 2020 - 2023
Member, Graduate Medical Education Committee, UTHSCH, 2017 - 2018
Member, House Staff Senate, 2015 - 2016
Resident Member, Harris Health/LBJ Hospital Cancer Committee, 2015 - 2017
Resident Member, Texas Medical Association Cancer Committee, 2015 - 2017
Resident Member, Memorial Hermann Hospital Cancer Committee, 2015 - 2017
Honors & Awards
| 2024 | Prioritizing Research Innovation and Mentoring Excellence (PRIME) Award, University of Texas MD Anderson Cancer Center |
| 2022 | Readers Choice: The Best of Blood Cancer Journal 2021 |
| 2022 | SITC Clinical Immuno-Oncology Network Workshop, Society for Immunotherapy of Cancer |
| 2020 | EHA Travel Grant Award, European Hematology Association |
| 2020 | Kimberly Patterson Fellowship for Excellence in Leukemia Research |
| 2020 | FDA Fellows' Day Workshop |
| 2020 | ASCO Young Investigator Award, Conquer Cancer Foundation |
| 2020 | ASCO Endowed Merit Award, ASCO Bristol-Myers Squibb |
| 2020 | Abstract Achievement Award, America Society of Hematology |
| 2019 | AACR Molecular Biology in Clinical Oncology Workshop, AACR |
| 2019 | Rising Star, Society for Translational Oncology Fellows' Forum (STOFF) |
| 2019 | Abstract Achievement Award, American Society of Hematology |
| 2019 | Shannon Timmins Endowed Fellowship in Leukemia Research |
| 2019 | Society for Translational Oncology Fellows’ Award |
| 2018 | Abstract Achievement Award, American Society of Hematology |
| 2018 | Leuka International Scholarship, European School of Hematology |
| 2018 | Methods in Clinical Cancer Research Workshop, AACR/ASCO |
| 2017 | Best Abstract Award, Society of Hematologic Oncology |
| 2017 | Best Research Poster, 2nd Position, American College of Physicians Texas Associates Day |
| 2017 | Future Leaders in Hematology Award for Clinical Research |
| 2017 | Abstract Achievement Award, American Society of Hematology |
| 2015 | Best Presentation, Resident and Fellow Section, American Medical Association Annual Research Symposium |
| 2010 | Best Paper for Pulmonary Medicine Poster Session, International Medical Students’ Research Conference |
| 2009 | National Science Academies’ Summer Research Fellowship |
| 2008 | Indian Council of Medical Research, Short Term Studentship |
| 2003 | National Merit Scholarship, Government of India |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Immunotherapy in Acute Myeloid Leukemia: Current Status and Future Directions. Invited. Zeev Estrov Leukemia Research Meeting. Houston, Texas, US.
- 2024. ELA026 TARGETING OF SIRP(+) IMMUNE CELLS RESULTS IN A HIGH RESPONSE RATE AND IMPROVED 2-MONTH SURVIVAL OF TREATMENT-NAÏVE MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PHASE 1 STUDY. Invited. Leukemia Planning Committee Meeting. Houston, Texas, US.
- 2023. Management of Secondary Hemophagocytic Lymphohistiocytosis. Invited. Frontiers in Critical Care Multidisciplinary Research Sessions. Houston, Texas, US.
- 2023. Cellular Immunotherapy in AML: Current Status and Future Directions. Conference. Zeev Estrov Leukemia Research Meeting. Houston, TX, US.
- 2023. Phase I Trial of ELA026 for Newly Diagnosed or Relapsed/Refractory Secondary Hemophagocytic Lymphohistiocytosis. Conference. Phase I Trial of ELA026 for Newly Diagnosed or Relapsed/Refractory Secondary Hemophagocytic Lymphohistiocytosis. Houston, TX, US.
- 2021. AML-297: Ten-Day Decitabine with Venetoclax vs Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score-Matched Analysis. Conference. AML-297: Ten-Day Decitabine with Venetoclax vs Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score-Matched Analysis, US.
- 2020. Prognostic Value of Measurable Residual Disease After Venetoclax and Decitabine in Acute Myeloid Leukemia. Leukemia Planning Committee Meeting. Houston, Texas, US.
- 2017. A Case Based Discussion on Management of Relapsed/Refractory IDH2 Mutant Acute Myeloid Leukemia. Conference. A Case Based Discussion on Management of Relapsed/Refractory IDH2 Mutant Acute Myeloid Leukemia. Houston, TX, US.
Regional Presentations
- 2011. Acute onset of vision loss in a patient with SLE. Conference. Acute onset of vision loss in a patient with SLE. Bethesda, MD, US.
National Presentations
- 2025. Abstract CT024: γ9δ2 T-cell (γδTC) activation and azacitidine-venetoclax (AV) for older/unfit adults with newly diagnosed (ND) acute myeloid leukemia (AML) induces high rates of complete remission (CR): Preliminary efficacy, safety, pharmacodynamics (PD) and dose selection of ICT01 in the phase 1 study EVICTION. Poster. Annual Meeting 2025. Chicago, IL, US.
- 2024. ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis. Conference. 66th ASH Annual Meeting and Exposition. San Dieho, California, US.
- 2024. ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction. Poster. 66th ASH Annual Meeting and Exposition. San Diego, California, US.
- 2023. Azacitidine, Venetoclax and Allogeneic NK Cells in Newly Diagnosed Acute Myeloid Leukemia (ADVENT-AML): An Investigator-Initiated Multicenter Phase Ib Trial. Poster. American Society of Haematology Annual Meeting. San Diego, CA, US.
- 2023. A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis. Poster. American Society of Haematology Annual Meeting. San Diego, CA, US.
- 2023. Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia. Poster. American Society of Haematology Annual Meeting. San Diego, CA, US.
- 2023. A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis. Invited. Annual Meeting of the Histiocyte Society. Athens, GR.
- 2022. Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial. Conference. Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial. New Orleans, LA, US.
- 2022. Intensive Chemotherapy vs. Venetoclax/Azacitidine-based Regimens in Elderly Patients with Secondary AML. Conference. DAVA Oncology. Amelia Island, FL, US.
- 2021. Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups. Conference. Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups. Virtual, US.
- 2021. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. Conference. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. Virtual, US.
- 2021. Evolution of Genomic Landscape in Acute Myeloid Leukemia after Decitabine and Venetoclax. Conference. Evolution of Genomic Landscape in Acute Myeloid Leukemia after Decitabine and Venetoclax. Virtual, US.
- 2020. Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia. Conference. Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia, US.
- 2020. Outcomes of De Novo Acute Myeloid Leukemia with Monocytic Differentiation (FAB M4/5) Treated with Venetoclax and Decitabine. Conference. Outcomes of De Novo Acute Myeloid Leukemia with Monocytic Differentiation (FAB M4/5) Treated with Venetoclax and Decitabine, US.
- 2020. Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial. Conference. Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial, US.
- 2020. Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial. Conference. Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial, US.
- 2020. Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis. Conference. Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis, US.
- 2020. Ten-day Decitabine with Venetoclax (DEC10-VEN) in AML and High-risk (HR) MDS. Conference. Ten-day Decitabine with Venetoclax (DEC10-VEN) in AML and High-risk (HR) MDS. Houston, TX, US.
- 2020. Impact of Stem-Cell Transplantation on Healthcare Utilization in Acute Myeloid Leukemia. Conference. Impact of Stem-Cell Transplantation on Healthcare Utilization in Acute Myeloid Leukemia, US.
- 2020. 10-Day Decitabine and Venetoclax (DEC10-VEN) Vs. Intensive Chemotherapy (IC) In Acute Myeloid Leukemia (AML): A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Conference. 10-Day Decitabine and Venetoclax (DEC10-VEN) Vs. Intensive Chemotherapy (IC) In Acute Myeloid Leukemia (AML): A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality, US.
- 2019. Ten-day Decitabine with Venetoclax (DEC0-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Conference. Ten-day Decitabine with Venetoclax (DEC0-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Orlando, FL, US.
- 2019. Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy. Conference. Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy. Orlando, FL, US.
- 2019. Outcomes of Relapsed or Refractory Acute Myeloid Leukemia After Frontline Hypomethylating Agent with Venetoclax Regimens. Conference. Outcomes of Relapsed or Refractory Acute Myeloid Leukemia After Frontline Hypomethylating Agent with Venetoclax Regimens. Orlando, FL, US.
- 2019. Outcomes in Molecular Subgroups and Resistance Patterns with Ten-day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. Conference. Outcomes in Molecular Subgroups and Resistance Patterns with Ten-day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. Orlando, GA, US.
- 2018. Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Conference. Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. San Diego, CA, US.
- 2018. Phase I/II Study of Ruxolitinib for Minimal Residual Disease in Chronic Myeloid Leukemia. Conference. Phase I/II Study of Ruxolitinib for Minimal Residual Disease in Chronic Myeloid Leukemia. San Diego, CA, US.
- 2018. Long-term Response, Safety, and Survival Outcomes with Frontline Dasatinib Therapy in Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP): Results of a Phase II Trial. Conference. Long-term Response, Safety, and Survival Outcomes with Frontline Dasatinib Therapy in Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP): Results of a Phase II Trial. Miami, FL, US.
- 2018. Risk of Infection with Ibrutinib in patients with Chronic Lymphocytic Leukemia (CLL): A systematic review and meta-analysis of phase III randomized controlled trials. Conference. Risk of Infection with Ibrutinib in patients with Chronic Lymphocytic Leukemia (CLL): A systematic review and meta-analysis of phase III randomized controlled trials. Houston, TX, US.
- 2018. MEK Inhibitor Binimetinib (MEK162) in Relapse and Refractory Acute Myeloid Leukemia: Results of a Phase I/II Study. Conference. MEK Inhibitor Binimetinib (MEK162) in Relapse and Refractory Acute Myeloid Leukemia: Results of a Phase I/II Study. Houston, TX, US.
- 2017. Hyper-CVAD Plus Ofatumumab as Frontline Therapy in CD0+ Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial. Conference. Hyper-CVAD Plus Ofatumumab as Frontline Therapy in CD0+ Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial. Atlanta, GA, US.
- 2017. The Clinical Benefit of Event-Free Survival (EFS) in Acute Myeloid Leukemia (AML): A Surrogate of Overall Survival (OS) or Meritorious on Its Own Right?. Conference. The Clinical Benefit of Event-Free Survival (EFS) in Acute Myeloid Leukemia (AML): A Surrogate of Overall Survival (OS) or Meritorious on Its Own Right?. Atlanta, GA, US.
- 2017. Frontline Ofatumumab with Hyper-CVAD in CD0+ Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. Conference. Frontline Ofatumumab with Hyper-CVAD in CD0+ Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. Houston, TX, US.
- 2017. Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. Conference. Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. Houston, TX, US.
- 2017. Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. Conference. Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. Houston, TX, US.
- 2017. Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial. Conference. Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial. Houston, TX, US.
- 2017. Updated results of frontline ofatumumab-hyper-CVAD in adults with CD20+ acute lymphoblastic leukemia. Conference. Updated results of frontline ofatumumab-hyper-CVAD in adults with CD20+ acute lymphoblastic leukemia. Chicago, IL, US.
- 2017. Phase II Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal Cell Carcinoma. Conference. Phase II Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal Cell Carcinoma. Houston, TX, US.
- 2016. Progressive Multifocal Leukoencephalopathy in a Patient with Polycythemia Vera taking Ruxolitinib. Conference. Progressive Multifocal Leukoencephalopathy in a Patient with Polycythemia Vera taking Ruxolitinib. Houston, TX, US.
- 2016. A Blue Finger and Hyponatremia Leading to a Diagnosis of Malignancy-Associated Marantic Endocarditis. Conference. A Blue Finger and Hyponatremia Leading to a Diagnosis of Malignancy-Associated Marantic Endocarditis. Hollywood, FL, US.
- 2016. Actinomycoses, An Unusual Suspect for Non-Resolving Pneumonia. Conference. Actinomycoses, An Unusual Suspect for Non-Resolving Pneumonia. Hollywood, FL, US.
- 2016. Characteristics and outcomes of patients with solid tumors undergoing investigational therapies who are discharged to hospice after an inpatient admission. Conference. Characteristics and outcomes of patients with solid tumors undergoing investigational therapies who are discharged to hospice after an inpatient admission. Hollywood, FL, US.
- 2015. Anti-tumor response to combined anti-angiogenic and cytotoxic chemotherapy in chromophobe renal cell carcinoma: Proteomic Correlates. Conference. Anti-tumor response to combined anti-angiogenic and cytotoxic chemotherapy in chromophobe renal cell carcinoma: Proteomic Correlates. Atlanta, GA, US.
International Presentations
- 2024. ELA026 TARGETING OF SIRP(+) IMMUNE CELLS RESULTS IN A HIGH RESPONSE RATE AND IMPROVED 2-MONTH SURVIVAL OF TREATMENT-NAÏVE MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PHASE 1 STUDY. Invited. European Haematology Association - Late Breaking Session. Madrid, ES.
- 2023. A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis. Invited. 39th Annual Meeting. Athens, GR.
- 2020. Decitabine and Venetoclax (DEC10-VEN) Vs. Intensive Chemotherapy (IC) In Acute Myeloid Leukemia (AML): A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Conference. Annual Meeting of the European Haematology Association, US.
- 2020. Impact of Stem-Cell Transplantation on Healthcare Utilization in Acute Myeloid Leukemia. Conference. Annual Meeting of the European Haematology Association, US.
- 2010. Mitochondrial Complex-I may be fundamentally altered in malignant cells. Conference. Third International Medical Students’ Research Conference. Coimbatore, IN.
- 2009. Alteration of coagulation profile in β-thalassemia major children. Podium presentation. Conference. The Second Asian and Third National Medical Students' Research Conference. Mangalore, IN.
Selected Publications
Peer-Reviewed Articles
- Daver N, Senapati J, Kantarjian HM, Wang B, Reville PK, Loghavi S, Yilmaz M, DiNardo CD, Kadia TM, Yassouf MY, Maiti A, Arora S, Montalban Bravo G, Tang G, Borthakur G, Sasaki K, Pemmaraju N, Alvarez J, Nogueras Gonzalez GM, Ning J, Issa GC, Konopleva M, Andreeff M, Ravandi F, Garcia-Manero G, Abbas HA. Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis. Clin Cancer Res, 2025. e-Pub 2025. PMID: 40198272.
- DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
- Ravandi F, Senapati J, Jain N, Short NJ, Kadia T, Borthakur G, Konopleva M, Wierda W, Huang X, Maiti A, Issa G, Balkin H, Garris R, Ferrajoli A, Garcia-Manero G, Alvarado Y, Kebriaei P, Jabbour E, Kantarjian HM. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia 38(12):2717-2721, 2024. e-Pub 2024. PMID: 39322712.
- Gruszczynska A, Maiti A, Miller CA, Ramakrishnan SM, Link DC, Uy GL, Petti AA, Hayes K, DiNardo CD, Ravandi F, Ley TJ, Spencer DH, Gao F, Konopleva MY, Welch JS. Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes. Haematologica, 2024. e-Pub 2024. PMID: 38618679.
- Bazinet, A, Garcia-Manero, G, Short, NJ, Alvarado, Y, Bataller, A, Abuasab, T, Islam, R, Montalbano, K, Issa, GC, Maiti, A, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Montalban Bravo, G, Rausch, CR, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Huang, X, Kantarjian, HM, Ravandi-Kashani, F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia. The Lancet Haematology 11(4):e276-e286, 2024. e-Pub 2024. PMID: 38452788.
- Senapati, J, Urrutia, S, Loghavi, S, Short, NJ, Issa, GC, Maiti, A, Abbas, HA, Daver, N, Pemmaraju, N, Pierce, S, Chien, KS, Sasaki, K, Kadia, TM, Hammond, DE, Borthakur, G, Patel, KP, Ravandi-Kashani, F, Kantarjian, HM, Garcia-Manero, G, DiNardo, C. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood 142(19):1647-1657, 2023. e-Pub 2023. PMID: 37441846.
- Short, NJ, Ong, F, Ravandi, F, Nogueras Gonzalez, G, Kadia, TM, Daver, N, DiNardo, C, Konopleva, M, Borthakur, G, Oran, B, Al-Atrash, G, Mehta, RS, Jabbour, EJ, Yilmaz, M, Issa, GC, Maiti, A, Champlin, RE, Kantarjian, HM, Shpall, E, Popat, UR. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Advances 7(14):3573-3581, 2023. e-Pub 2023. PMID: 37104058.
- Pouleau, B, Estoppey, C, Suere, P, Nallet, E, Laurendon, A, Monney, T, Pais Ferreira, D, Drake, A, Carretero-Iglesia, L, Macoin, J, Berret, J, Pihlgren, M, Doucey, MA, Gudi, GS, Menon, V, Udupa, V, Maiti, A, Borthakur, G, Srivastava, A, Blein, S, Mbow, ML, Matthes, T, Kaya, Z, Edwards, CM, Edwards, JR, Menoret, E, Kervoëlen, C, Pellat-Deceunynck, C, Moreau, P, Zhukovsky, E, Perro, M, Chimen, M. Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma. Blood 142(3):260-273, 2023. e-Pub 2023. PMID: 37192303.
- Bazinet, A, Kadia, TM, Short, NJ, Borthakur, G, Wang, SA, Wang, W, Loghavi, S, Jorgensen, JL, Patel, KP, DiNardo, C, Daver, N, Alvarado, Y, Haddad, FG, Pierce, S, Gonzalez, GN, Maiti, A, Sasaki, K, Yilmaz, M, Thompson, PA, Wierda, WG, Garcia-Manero, G, Andreeff, M, Jabbour, EJ, Konopleva, M, Huang, X, Kantarjian, HM, Ravandi-Kashani, F. Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Advances 7(13):3284-3296, 2023. e-Pub 2023. PMID: 36884300.
- Maiti A, Pal AJ. Spin-Selective Charge Transport in Lead-Free Chiral Perovskites: The Key towards High-Anisotropy in Circularly-Polarized Light Detection. Angew Chem Int Ed Engl 61(52):e202214161, 2022. e-Pub 2022. PMID: 36325645.
- Maiti A, Pal AJ. Quasi-2D Ruddlesden-Popper Lead Halide Perovskites: How Edge Matters. J Phys Chem Lett 13(42):9875-9882, 2022. e-Pub 2022. PMID: 36251849.
- Venugopal, S, Kantarjian, HM, Maiti, A, Short, NJ, Montalban Bravo, G, Alvarado, Y, Chien, KS, Kanagal Shamanna, R, Pemmaraju, N, Daver, N, Kadia, TM, Borthakur, G, Jabbour, EJ, Garcia-Manero, G. MDS-520 A Phase I/II Study of Venetoclax in Combination With ASTX727 (Decitabine/Cedazuridine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Clinical Lymphoma, Myeloma and Leukemia 22:S321, 2022. e-Pub 2022. PMID: 36163977.
- Goswamy R, Ajufo H, Maiti A, Brown R, Juneja H, Apostolidou E. Refractory Hydroa Vacciniforme-like Lymphoma: Biological Insights from Morphoproteomic Analysis. Int J Hematol Oncol Stem Cell Res 16(3):177-183, 2022. e-Pub 2022. PMID: 36694700.
- Goswamy, R, Ajufo, HO, Maiti, A, Brown, RE, Juneja, HS, Apostolidou, E. Refractory Hydroa Vacciniforme-Like Lymphoma. International Journal of Hematology-Oncology and Stem Cell Research 16(3):174-180, 2022. e-Pub 2022.
- Dan S, Maiti A, Chatterjee S, Pal AJ. Origin of bandgap bowing in Cs(2)Na(1-x)Ag(x)BiCl(6)double perovskite solid-state alloys: a paradigm through scanning tunneling spectroscopy. J Phys Condens Matter 33(48), 2021. e-Pub 2021. PMID: 34479226.
- Maiti A, Khatun S, Pal AJ. Rashba Band Splitting in CH(3)NH(3)PbI(3): An Insight from Spin-Polarized Scanning Tunneling Spectroscopy. Nano Lett 20(1):292-299, 2020. e-Pub 2020. PMID: 31841346.
Review Articles
- Cuglievan B, Kantarjian H, Rubnitz JE, Cooper TM, Zwaan CM, Pollard JA, DiNardo CD, Kadia TM, Guest E, Short NJ, McCall D, Daver N, Nunez C, Haddad FG, Garcia M, Bhalla KN, Maiti A, Catueno S, Fiskus W, Carter BZ, Gibson A, Roth M, Khazal S, Tewari P, Abbas HA, Bourgeois W, Andreeff M, Shukla NN, Truong DD, Connors J, Ludwig JA, Stutterheim J, Salzer E, Juul-Dam KL, Sasaki K, Mahadeo KM, Tasian SK, Borthakur G, Dickson S, Jain N, Jabbour E, Meshinchi S, Garcia-Manero G, Ravandi F, Stein EM, Kolb EA, Issa GC. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. Leukemia 38(10):2073-2084, 2024. e-Pub 2024. PMID: 39179671.
- Parmar, K, Kundu, R, Maiti, A, Ball, S. Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia. Leukemia Research 144, 2024. e-Pub 2024. PMID: 38986173.
- Rao, A, Agrawal, A, Borthakur, G, Battula, VL, Maiti, A. Gamma delta T cells in acute myeloid leukemia. Journal for immunotherapy of cancer 12(2), 2024. e-Pub 2024. PMID: 38417915.
- Cuglievan, B, Connors, JS, He, J, Khazal, SJ, Yedururi, S, Dai, J, Garces, S, Quesada, AE, Roth, M, Garcia, M, McCall, DC, Gibson, A, Ragoonanan, D, Petropoulos, D, Tewari, P, Nunez, CA, Mahadeo, KM, Tasian, SK, Lamble, AJ, Pawlowska, A, Hammond, DE, Maiti, A, Haddad, FG, Senapati, J, Daver, N, Gangat, N, Konopleva, M, Meshinchi, S, Pemmaraju, N. Blastic plasmacytoid dendritic cell neoplasm: A comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia 37(9):1767-1778, 2023. e-Pub 2023. PMID: 37452102.
- Fedorov, K, Maiti, A, Konopleva, M. Targeting FLT3 Mutation in Acute Myeloid Leukemia. Cancers 15(8), 2023. e-Pub 2023. PMID: 37190240.
- Maiti A, Pal AJ. Carrier recombination in CH(3)NH(3)PbI(3): why is it a slow process?. Rep Prog Phys 85(2), 2022. e-Pub 2022. PMID: 35038679.
Professional Educational Materials
- Daver N, Maiti A. Immunotherapies and Cellular Therapies for Patients with Acute Myeloid Leukemia. MD Anderson Cancer Center, 2021.
- Maiti A, Ravandi F. Oral Therapies for Acute Myeloid Leukemia. MDACC, 2021.
Abstracts
- Nishida, Y, Scruggs, DA, Ayoub, E, Patsilevas, T, Ruvolo, VR, Mak, PY, Carter, BZ, Boettcher, S, Maiti, A, Zhou, Q, Yang, Z, Yan, H, Ma, L, Andreeff, M. AML-147 C-MYC Targeting by Degradation. Clinical Lymphoma, Myeloma and Leukemia 22:S218, 2022. e-Pub 2022. PMID: 36163775.
Book Chapters
- Maiti A, Andreeff M. Emerging approaches to treat high-risk acute myeloid leukemia. In: Diagnostic and management of high-risk acute myeloblastic leukemia in adult patients. Minerva Medica, 2023.
Letters to the Editor
- Senapati J, Garcia-Manero G, DiNardo CD, Deshmukh I, Borthakur G, Kadia TM, Jabbour E, Short NJ, Abbas HA, Pemmaraju N, Jain N, Haddad FG, Issa GC, Maiti A, Shpall E, Popat U, Loghavi S, Tang G, Yilmaz M, Alvarado Y, Montalban-Bravo G, Ravandi F, Kantarjian HM, Daver NG. Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia. Bone Marrow Transplant 60: 910-913, 2025.
- Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol 99: 792-796, 2024.
- Hammond, DE, Loghavi, S, Wang, SA, Konopleva, M, Kadia, TM, Daver, N, Ohanian, M, Issa, GC, Alvarado, Y, Short, NJ, Sasaki, K, Pemmaraju, N, Montalban Bravo, G, Lachowiez, C, Maiti, A, Garcia-Manero, G, Jabbour, EJ, Borthakur, G, Ravandi-Kashani, F, Takahashi, K, Pierce, SR, Kantarjian, HM, DiNardo, C. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood cancer journal 13, 2023.
Patient Reviews
CV information above last modified July 24, 2025